Emergent Biosolutions Inc (N:EBS)

Feb 20, 2020 04:31 pm ET
Emergent BioSolutions Reports Financial Results for Fourth Quarter and Full Year 2019
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2019. FINANCIAL HIGHLIGHTS (in millions)Q4 2019(unaudited)Q4 2018(unaudited)$ Change% ChangeTotal Revenues$360.4$270.7$89.733.1%Pre-tax...
Feb 03, 2020 04:30 pm ET
Emergent BioSolutions to Release Fourth Quarter and Full Year 2019 Financial Results and Conduct a Conference Call on February 20, 2020
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 20, 2020 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full year 2019, recent business developments, financial outlook...
Jan 31, 2020 09:26 am ET
Emergent BioSolutions Receives Positive CHMP Opinion for Vaxchora; Anticipates Near-Term Approval by European Medicines Agency
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for the approval of the company’s single-dose oral cholera...
Jan 13, 2020 06:40 am ET
Emergent BioSolutions Receives EMA Agreement for Proposed Development Path of Investigational Chikungunya VLP Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced that it has received agreement from the European Medicines Agency (EMA) to pursue its proposed development plan for its chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate. The company...
Jan 13, 2020 06:30 am ET
Emergent BioSolutions Announces Preliminary 2019 Financial Results and Provides 2020 Financial Forecast
Emergent BioSolutions Inc. (NYSE: EBS) today announced selected preliminary unaudited 2019 financial results and its financial forecast for 2020. Robert G. Kramer Sr., president and chief executive officer of Emergent BioSolutions Inc., stated,...
Jan 06, 2020 06:30 am ET
Emergent BioSolutions to Participate in Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following investor conferences during the first quarter of 2020: 38th Annual J.P. Morgan Healthcare...
Dec 20, 2019 01:00 pm ET
Emergent BioSolutions Board Members Dr. Sue Bailey and Dr. Kathryn C. Zoon Named Most Influential Corporate Directors
Emergent BioSolutions Inc. (NYSE: EBS) today announced that two members of its board of directors – Dr. Sue Bailey and Dr. Kathryn C. Zoon – have been recognized as WomenInc. magazine's 2019 Most Influential Corporate Directors.  “Sue and Kathy...
Nov 22, 2019 08:19 am ET
Emergent BioSolutions Presents Positive Immunogenicity Results From Phase 2 Study of Its Investigational Chikungunya VLP Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced updated results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate...
Nov 21, 2019 04:05 pm ET
Emergent BioSolutions Announces Growth Strategy and 2024 Goals at Analyst and Investor Day
Emergent BioSolutions Inc. (NYSE: EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and operational goals during the company’s Analyst and Investor Day held in New York City. Emergent’s senior...
Nov 18, 2019 06:30 am ET
Emergent BioSolutions to Host 2019 Analyst and Investor Day
Emergent BioSolutions Inc. (NYSE: EBS) will be hosting an analyst and investor day on November 21, 2019 from 8:00 AM EST to 2:00 PM EST in New York City. This event is designed for sellside research analysts and institutional investors and requires...
Nov 06, 2019 04:05 pm ET
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2019
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the third quarter and nine months ended September 30, 2019. FINANCIAL HIGHLIGHTS (unaudited) (in millions)Q3 2019Q3 2018Total Revenues$311.8$173.6Pre-tax Income$58.9$21.5Net...
Oct 21, 2019 06:30 am ET
Emergent BioSolutions to Host 2019 Analyst & Investor Day
Emergent BioSolutions Inc. (NYSE: EBS) today announced that the company will host an analyst and investor day on November 21, 2019 in New York City. This event, which is designed for sellside research analysts and institutional investors, will...
Oct 10, 2019 06:38 am ET
Emergent BioSolutions Receives EMA Prime Designation for Its Chikungunya Virus VLP Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company’s chikungunya virus (CHIKV) virus-like particle (VLP) vaccine candidate, CHIKV VLP, was granted PRIority MEdicines, or PRIME, designation by the Committee for Medicinal Products...
Oct 09, 2019 06:30 am ET
Emergent BioSolutions to Release Third Quarter 2019 Financial Results and Conduct a Conference Call on November 6, 2019
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2019, recent business developments, revenue guidance for the...
Sep 27, 2019 06:35 am ET
Emergent BioSolutions Receives NIH Research Grant to Further Develop AP007, Its Development Stage Sustained-Release Nalmefene Treatment for Opioid Use Disorder
Emergent BioSolutions Inc. (NYSE: EBS) today announced a research grant awarded by the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), U.S. Department of Health and Human Services, valued at...
Sep 26, 2019 09:27 am ET
Emergent BioSolutions to Participate in Cantor Fitzgerald Global Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the Cantor Fitzgerald Global Healthcare Conference 2019 to be held in New York from October 2 to 4. Presentation date...
Sep 25, 2019 04:15 pm ET
Emergent BioSolutions Awarded $20 Million to Develop Diazepam Auto-Injector to Treat Nerve Agent-Induced Seizures for U.S. Department of Defense
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded approximately $20 million to develop and manufacture an auto-injector containing diazepam (5 mg/mL) to treat nerve agent-induced seizures. Emergent’s device is being...
Sep 03, 2019 06:30 am ET
Emergent BioSolutions Awarded 10-Year HHS Contract to Deliver ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) Into the Strategic National Stockpile
In support of the U.S. government’s policy to maintain a stockpile to be able to protect every American from smallpox, Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness...
Aug 14, 2019 04:15 pm ET
Emergent BioSolutions to Participate in Series of Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the third quarter of 2019: Three Part Advisors – Midwest IDEAS...
Aug 01, 2019 04:05 pm ET
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months Ended June 30, 2019
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the second quarter and six months ended June 30, 2019. FINANCIAL HIGHLIGHTS (unaudited) (in millions)Q2 2019Q2 2018Total Revenues$243.2 $220.2Pre-tax (Loss)...
Jul 30, 2019 04:42 pm ET
Emergent BioSolutions Announces Exercise by BARDA of the First Contract Option, Valued at $261 Million, to Procure Doses of AV7909 Anthrax Vaccine Candidate for the Strategic National Stockpile
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has exercised its first contract option valued at $261 million to procure doses of AV7909 (anthrax vaccine adsorbed with...
Jul 18, 2019 06:30 am ET
Emergent BioSolutions to Release Second Quarter 2019 Financial Results and Conduct a Conference Call on August 1, 2019
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, August 1, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2019, recent business developments, revenue guidance for the third...
Jun 04, 2019 04:05 pm ET
Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine
Emergent BioSolutions Inc. (NYSE:EBS) today announced approval by the U.S. Food and Drug Administration (FDA) of the Prior Approval Supplement (PAS) submitted by the company for its oral cholera vaccine, Vaxchora® (Cholera Vaccine, Live, Oral). The...
Jun 03, 2019 06:30 am ET
Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous (VIGIV) in Support of Smallpox Preparedness
Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $535 million...
May 20, 2019 04:05 pm ET
Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine Vivotif® (Typhoid Vaccine Live Oral Ty21a) in five additional European Union Member States, including...
May 20, 2019 06:30 am ET
Emergent BioSolutions to Participate in Series of Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the second quarter of 2019: RBC Capital Markets – 2019 Global Healthcare...
May 15, 2019 04:05 pm ET
Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has informed the company that it will begin procuring AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) for...
May 09, 2019 06:30 am ET
Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available
Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2019 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard,...
May 02, 2019 04:05 pm ET
Emergent BioSolutions Reports First Quarter 2019 Financial Results
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the three months ended March 31, 2019. FINANCIAL HIGHLIGHTS (in millions) Q1 2019(unaudited) Q1 2018(unaudited)Total Revenues $190.6 $117.8Pre-tax Loss $(37.8) $(9.4)Net...
Apr 19, 2019 08:20 am ET
Analysis: Positioning to Benefit within Orchid Island Capital, Emergent Biosolutions, Intelligent, USD Partners LP, Red Violet, and Ascent Capital Group — Research Highlights Growth, Revenue, and Cons
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Orchid Island Capital, Inc. (NYSE:ORC), Emergent Biosolutions Inc....
Apr 18, 2019 07:22 am ET
Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, May 2, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2019, recent business developments, revenue guidance for the second...
Apr 16, 2019 06:30 am ET
Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV-VLP) vaccine candidate...
Mar 19, 2019 06:30 am ET
Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and safety of AV7909 (anthrax vaccine adsorbed with CPG 7909 adjuvant) following a two-dose schedule...
Feb 28, 2019 04:45 pm ET
Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the U.S. Department of State to establish a long-term, reliable, and stable supply chain for medical...
Feb 21, 2019 04:05 pm ET
Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018. FINANCIAL HIGHLIGHTS (in millions)Q4 2018(unaudited)Q4 2017(unaudited)Total Revenues$270.7$193.8Pretax Income$3.6$51.9Net Income...
Feb 15, 2019 07:50 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within CVS Health, Solaris Oilfield Infrastructure, SK Telecom Co., Energizer, Emergent Biosolutions, and Quad Graphics — New Research Emph
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CVS Health Corporation (NYSE:CVS), Solaris Oilfield Infrastructure,...
Feb 12, 2019 06:30 am ET
Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors
Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Seamus Mulligan to the company’s Board of Directors effective March 19, 2019. Mr. Mulligan was a co-founder and principal investor of Adapt Pharma Ltd. and served as its...
Feb 07, 2019 09:35 am ET
Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 21, 2019 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full year 2018, recent business developments, financial outlook...
Jan 24, 2019 07:00 am ET
Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors
Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Robert G. Kramer, Sr. to the company’s Board of Directors. Mr. Kramer currently serves as Emergent’s president and COO. Effective April 1, 2019, Mr. Kramer will assume the...
Jan 07, 2019 06:30 am ET
Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial Forecast
Emergent BioSolutions Inc. (NYSE: EBS) today announced selected preliminary unaudited 2018 financial results and its financial forecast for 2019. Daniel J. Abdun-Nabi, chief executive officer of Emergent BioSolutions, said, “Our preliminary...
Jan 04, 2019 07:00 am ET
Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO
Emergent BioSolutions Inc. (NYSE: EBS) today announced that its CEO Daniel J. Abdun-Nabi will be retiring and that its board of directors has unanimously appointed Robert G. Kramer, Sr., the company’s current president and COO, to succeed him as...
Dec 28, 2018 09:01 am ET
Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax™
Emergent BioSolutions Inc. (NYSE:EBS) announced today the submission of an application to the U.S. Food and Drug Administration (FDA) for potential emergency use of NuThrax™ (anthrax vaccine adsorbed with CPG 7909 adjuvant) in the event of a public...
Dec 17, 2018 04:10 pm ET
Emergent BioSolutions Receives Health Canada Approval of BioThrax® (Anthrax Vaccine Adsorbed)
Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its anthrax vaccine, BioThrax® (Anthrax Vaccine Adsorbed). BioThrax is indicated for active immunization for the...
Dec 04, 2018 08:15 am ET
Detailed Research: Economic Perspectives on United Technologies, Walmart, Invitae, Emergent Biosolutions, U.S. Physical Therapy, and Amdocs — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of United Technologies Corporation (NYSE:UTX), Walmart Inc. (NYSE:WMT),...
Nov 19, 2018 04:22 pm ET
Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus
Emergent BioSolutions Inc. (NYSE: EBS) and Valneva SE (VLA) today announced positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus. The highly purified inactivated vaccine candidate,...
Nov 06, 2018 07:00 am ET
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the fourth quarter and early portion of the first quarter of 2019: JP Morgan...
Nov 01, 2018 04:30 pm ET
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months of 2018
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and nine months ended September 30, 2018. FINANCIAL HIGHLIGHTS    (in millions, except per share value)Q3 2018(unaudited)Q3 2017(unaudited)Total...
Oct 25, 2018 07:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within StoneMor Partners, Catalyst Biosciences, Kennametal, Emergent Biosolutions, Kimball International, and Tailored Brands — New Researc
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of StoneMor Partners L.P. (NYSE:STON), Catalyst Biosciences, Inc....
Oct 24, 2018 02:30 pm ET
Emergent BioSolutions to Offer All Public Libraries and YMCAs in the U.S. Free Opioid Awareness Education and NARCAN® (naloxone HCl) Nasal Spray
Emergent BioSolutions Inc. (NYSE: EBS) today announced, through its subsidiary Adapt Pharma, the launch of two new programs to raise public awareness of the potential risks of opioids and the importance of preparedness in case of an opioid...
Oct 15, 2018 04:30 pm ET
Emergent BioSolutions Completes Acquisition of Adapt Pharma and Flagship Product Narcan® (Naloxone HCI) Nasal Spray
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has completed its acquisition of Adapt Pharma and its flagship product NARCAN® (naloxone HCl) Nasal Spray, the first and only intranasal form of naloxone approved by the U.S. Food and...
Oct 11, 2018 06:30 am ET
Emergent BioSolutions to Release Third Quarter 2018 Financial Results and Conduct a Conference Call on November 1, 2018
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 1, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the third quarter of 2018, recent business developments, revenue guidance for the fourth...
Oct 04, 2018 06:27 pm ET
Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has completed its acquisition of PaxVax, a company focused on developing, manufacturing, and commercializing specialty vaccines that protect against existing and emerging infectious...
Sep 05, 2018 07:45 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Emergent Biosolutions, LGI Homes, Surgery Partners, Overseas Shipholding Group, National Commerce, and comScore — New Research Empha
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Emergent Biosolutions Inc. (NYSE:EBS), LGI Homes, Inc. (NASDAQ:LGIH),...
Aug 28, 2018 04:31 pm ET
Emergent BioSolutions Joins Effort to Combat National Public Health Threat From Opioid Overdose Through Acquisition of Adapt Pharma and Its Flagship Product NARCAN® (naloxone HCl) Nasal Spray
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire Adapt Pharma and its flagship product NARCAN® (naloxone HCl) Nasal Spray, the first and only needle-free formulation of naloxone approved by...
Aug 17, 2018 07:00 am ET
Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences
Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the third quarter and early portion of the fourth quarter of 2018: Three...
Aug 16, 2018 06:15 am ET
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE: EBS) under which they will receive up to USD$36 million to advance the development...
Aug 15, 2018 08:25 am ET
Report: Developing Opportunities within RA PHARMCTL INC, Oclaro, Emergent Biosolutions, Kennametal, Instructure, and Donegal Group — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of RA PHARMCTL INC (NASDAQ:RARX), Oclaro, Inc. (NASDAQ:OCLR), Emergent...
Aug 09, 2018 06:36 am ET
Emergent BioSolutions to Acquire PaxVax from Cerberus Capital Management
REDWOOD CITY, Calif., Aug. 9, 2018 /PRNewswire/ -- PaxVax today announced that it has entered into a definitive agreement to be acquired by Emergent BioSolutions (NYSE: EBS) ("Emergent"). PaxVax is majority owned by an affiliate of Cerberus Capital Management, L.P. ("Cerberus"), a global leader in alternative investing, and Ignition Growth Capital is a minority shareholder in the company....
Aug 09, 2018 06:30 am ET
Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement to acquire PaxVax, a company focused on specialty vaccines that protect against existing and emerging infectious diseases, for an all-cash consideration of...
Aug 02, 2018 04:30 pm ET
Emergent BioSolutions Reports Financial Results for Second Quarter and Six Months of 2018
Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and six months ended June 30, 2018.    FINANCIAL HIGHLIGHTS      (in millions, except per share value)Q2 2018(unaudited)Q2 2017(unaudited)Total...
Jul 31, 2018 04:30 pm ET
Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic
Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1 clinical study to evaluate the safety and pharmacokinetics of ZIKV-IG, the company’s anti-Zika virus immune globulin, being developed as a therapeutic intervention...
Jul 18, 2018 04:30 pm ET
Emergent BioSolutions to Release Second Quarter 2018 Financial Results and Conduct a Conference Call on August 2, 2018
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 2, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2018, recent business developments, revenue guidance for the third...
Jun 08, 2018 06:30 am ET
Emergent BioSolutions to Participate in the Goldman Sachs 39th Annual Global Healthcare Conference
Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will present a corporate overview and discuss recent business developments during a fireside chat at the Goldman Sachs 39th Annual Global...
Jun 07, 2018 06:30 am ET
Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility
Emergent BioSolutions Inc. (NYSE:EBS) today announced the beginning of a $50 million expansion to the company’s Camden fill/finish facility located in Baltimore, Md. The multi-year expansion is expected to be completed in 2021, and will...
May 24, 2018 08:15 am ET
Consolidated Research: 2018 Summary Expectations for PGT, National Commerce, CrossAmerica Partners LP, Destination XL Group, Allegiance Bancshares, and Emergent Biosolutions — Fundamental Analysis, Ke
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PGT, Inc. (NYSE:PGTI), National Commerce Corporation (NASDAQ:NCOM),...
May 24, 2018 06:11 am ET
CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine
CEPI—the Coalition for Epidemic Preparedness Innovations—today announced a collaboration with Profectus BioSciences, Inc. and Emergent BioSolutions Inc. (NYSE:EBS) under which Profectus and Emergent will receive up to $25 million to advance the...
May 10, 2018 04:50 pm ET
Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 24, 2018 at 9:00 AM EDT; Webcast Will Be Available
Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 24, 2018 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard,...
May 03, 2018 04:30 pm ET
Emergent BioSolutions Reports First Quarter 2018 Financial Results
Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and three months ended March 31, 2018. FINANCIAL HIGHLIGHTS (in millions, except per share value)Q1 2018(unaudited)Q1 2017(unaudited)Total...
Apr 19, 2018 06:30 am ET
Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018
GAITHERSBURG, Md., April 19, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, May 3, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the first quarter of 2018,...
Apr 12, 2018 06:30 am ET
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries
Emergent BioSolutions Inc. (NYSE:EBS) today announced the successful completion of the Mutual Recognition Procedure (MRP) for market authorisation of BioThrax® (Anthrax Vaccine Adsorbed) in five Concerned Member States (CMS) within the European Union (EU), including Italy, the Netherlands, Poland, the U.K., and France (where it will be marketed as BaciThrax™). Emergent filed the mutual recognition application based on the existing Marketing Authorisation of BioThrax in Germany granted by the Paul-Ehrlich-Institut. Following the positi
Apr 12, 2018 06:30 am ET
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European Countries
GAITHERSBURG, Md., April 12, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the successful completion of the Mutual Recognition Procedure (MRP) for market authorization of BioThrax® (Anthrax Vaccine Adsorbed) in five Concerned Member States (CMS) within the...
Apr 02, 2018 08:10 am ET
New Research Coverage Highlights SITO Mobile, Emergent Biosolutions, Instructure, First Financial Bankshares, Jones Lang LaSalle, and QAD — Consolidated Revenues, Company Growth, and Expectations for
NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SITO Mobile, Ltd. (NASDAQ:SITO), Emergent Biosolutions...
Mar 26, 2018 04:30 pm ET
Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy
GAITHERSBURG, Md., March 26, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced executive management changes that continue to align its organizational structure to its long-term strategy and to the achievement of its near- and long-term growth...
Mar 22, 2018 04:30 pm ET
Emergent BioSolutions to Implement Stock Repurchase Program for up to $50 Million of Its Common Stock
GAITHERSBURG, Md., March 22, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the company’s management to implement a stock repurchase program for up to $50 million of the company's common stock...
Feb 28, 2018 06:45 am ET
Emergent BioSolutions Awarded One-Year CDC Contract Valued at $26 Million for Vaccinia Immune Globulin Program
GAITHERSBURG, Md., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a contract award by the Centers for Disease Control and Prevention (CDC) valued at $26 million over 12 months for the continued supply of...
Feb 26, 2018 04:15 pm ET
Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus
GAITHERSBURG, Md. and LYON, France, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) and Valneva SE (Euronext Paris:VLA) today announced the initiation of a Phase 1 clinical trial in the U.S. to evaluate the safety and...
Feb 22, 2018 04:46 pm ET
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results
GAITHERSBURG, Md., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31, 2017.
Feb 22, 2018 01:00 pm ET
Emergent BioSolutions Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Emergent BioSolutions Inc. (NYSE: EBS) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018, at 5:00 PM Eastern Time.
Feb 08, 2018 06:30 am ET
Emergent BioSolutions to Release Fourth Quarter and Full Year 2017 Financial Results and Conduct a Conference Call on February 22, 2018
GAITHERSBURG, Md., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 22, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the fourth quarter and full...
Jan 31, 2018 08:20 am ET
New Research: Key Drivers of Growth for Cavco Industries, National Commerce, The Providence Service, Cisco, Immunomedics, and Emergent Biosolutions — Factors of Influence, Major Initiatives and Sustai
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cavco Industries, Inc. (NASDAQ:CVCO), National Commerce...
Jan 08, 2018 06:30 am ET
Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook
GAITHERSBURG, Md., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced preliminary unaudited 2017 financial results and guidance for 2018.
Jan 04, 2018 07:00 am ET
Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
GAITHERSBURG, Md., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 2 dose ranging study to evaluate the safety, pharmacokinetics, and clinical benefit of FLU-IGIV, the company’s anti-influenza immune globulin...
Jan 03, 2018 07:00 am ET
Emergent BioSolutions to Participate in First Quarter 2018 Investor Conferences
GAITHERSBURG, Md., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the first quarter of 2018:
Dec 12, 2017 07:00 am ET
Emergent BioSolutions Awarded Department of National Defence Contract to Supply Anthrasil to the Canadian Government
Health Canada approves Anthrasil® under Extraordinary Use New Drug Regulations
Nov 30, 2017 07:00 am ET
Emergent BioSolutions to Host 2017 Analyst & Investor Day
GAITHERSBURG, Md., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the company will host an analyst and investor day on December 7, 2017 in New York City.
Nov 20, 2017 07:00 am ET
Emergent BioSolutions Receives FDA Approval to Manufacture ACAM2000 at Canton, Massachusetts Facility
GAITHERSBURG, Md., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the manufacture of ACAM2000®, (Smallpox (Vaccinia) Vaccine,...
Nov 14, 2017 05:38 pm ET
Emergent BioSolutions Announces Notice of Termination of Conversion Rights of 2.875% Convertible Senior Notes Due 2021
GAITHERSBURG, Md., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has issued a Notice of Termination of Conversion Rights for all of its outstanding 2.875% Convertible Senior Notes due 2021 (“Notes”) and...
Nov 02, 2017 04:15 pm ET
Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
GAITHERSBURG, Md., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2017....
Nov 02, 2017 04:15 pm ET
Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance
GAITHERSBURG, Md., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2017.
Sep 25, 2017 07:00 am ET
Emergent BioSolutions to Supply DoD With Chemical Threat Countermeasure RSDL Under Five-Year Follow-On Contract Valued at Up to $171 Million
GAITHERSBURG, Md., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a five-year follow-on contract valued at up to approximately $171 million by the U.S. Department of Defense (DoD) to supply RSDL® (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military. The RSDL Kit is intended to remove or neutralize chemical warfare agents and T-2 toxin from the skin....
Sep 18, 2017 08:00 am ET
Emergent BioSolutions Awarded $63 Million BARDA Contract to Develop Treatment for Cyanide Exposure
GAITHERSBURG, Md., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a contract valued at approximately $63 million by the Biomedical Advanced Research and Development Authority (BARDA) to develop an antidote spray device for the treatment of known or suspected acute cyanide poisoning. The single-use intranasal spray device will deliver a stabilized form of isoamyl nitrite (SIAN) and is intended for use by first responders and medical personnel following a cyanide incident....
Aug 03, 2017 04:15 pm ET
Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance
GAITHERSBURG, Md., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and six months ended June 30, 2017....
Jul 31, 2017 04:15 pm ET
Emergent BioSolutions Awarded $23 Million to Develop Novel Multi-Drug Auto-Injector for U.S. Department of Defense
GAITHERSBURG, Md., July 31, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded approximately $23 million to develop a novel multi-drug auto-injector for nerve agent antidote delivery. Emergent’s device is being designed for intramuscular self- or buddy-administration of antidotes for use in military environments and for civilian emergencies....
Jul 26, 2017 04:15 pm ET
Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology
Parties to collaborate through Phase 1 clinical development Phase 1 trial expected to commence in late 2017 or early 2018 GAITHERSBURG, Md., July 26, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced a licensing agreement with Valneva SE for global exclusive rights to Valneva’s Zika vaccine technology, ZIKV. Emergent and Valneva will co-develop ZIKV-VLA1601, a highly purified inactivated vaccine candidate against the Zika virus, from preclinical development through completion of a Phase 1 safety and immunogenicity clinical trial. ZIKV-VLA1601, which has shown to...
Jul 19, 2017 04:15 pm ET
Emergent BioSolutions to Acquire Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK
All-cash transaction includes a $76 million upfront payment and up to $20 million in product sale and manufacturing-related milestone paymentsAddition of licensed anthrax therapeutic expands Emergent’s portfolio of approved medical countermeasures addressing public health threatsEmergent plans to assume responsibility for a multi-year contract with BARDA, valued at up to approximately $130 million, to supply raxibacumab to the SNSBulk and fill/finish manufacturing expected to be transferred to existing Emergent facilities located in Baltimore, MarylandTransaction expected to be accretive upo...
May 11, 2017 07:00 am ET
Emergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be Available
GAITHERSBURG, Md., May 11, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 25, 2017 beginning at 9:00 AM EDT at the Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878....
May 04, 2017 04:15 pm ET
Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance
GAITHERSBURG, Md., May 04, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and three months ended March 31, 2017....
Feb 23, 2017 04:15 pm ET
Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals
GAITHERSBURG, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and twelve months ended December 31, 2016....
Feb 01, 2017 07:00 am ET
Emergent BioSolutions Initiates NIAID-Funded Phase 1b Clinical Study to Evaluate Broad-Spectrum Antiviral UV-4B for Dengue
GAITHERSBURG, Md., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b multiple ascending dose study to evaluate the safety and tolerability of UV-4B, the company’s novel antiviral candidate being developed as a potential oral treatment for dengue viral infection. This study, which will enroll 40 healthy adults in U.S. sites, follows a successful Phase 1a single ascending dose clinical study completed in 2016. Preclinical studies have shown that UV-4B is active in vitro against all four dengue virus subtypes and in vivo studi...
Dec 08, 2016 05:12 pm ET
Emergent BioSolutions to Support HHS Anthrax Preparedness Strategy With Up to $1 Billion in BioThrax Deliveries to the Strategic National Stockpile
Company signs follow-on contract with CDC valued at up to $911 million to supply to the SNS approximately 29.4 million doses of BioThrax through September 2021BARDA issues notice of intent to separately procure approximately $100 million of BioThrax for the SNS over 24 months from contract award, which is expected in 1H 2017These actions, together with the recently awarded BARDA contract for NuThrax, reflect the U.S. government’s intention to transition the stockpile of anthrax vaccines from BioThrax to NuThraxCompany re-establishes 2016 financial guidance GAITHERSBURG, Md., Dec. 08, 2016 ...
Nov 15, 2016 09:49 am ET
Integrated BioTherapeutics, Inc. Announces Licensing Agreement with Emergent BioSolutions for Development of Equine Immunoglobulin Therapeutics for Filovirus Infections
ROCKVILLE, Md., Nov. 15, 2016 /PRNewswire/ -- Integrated BioTherapeutics (IBT) announced today that it has entered into an exclusive worldwide license agreement with Emergent BioSolutions Inc. (NYSE: EBS) whereby Emergent will gain exclusive rights to use IBT's proprietary vaccine antigens and know-how in a joint research, development, and manufacturing collaboration focused on an equine-based hyperimmunoglobulin for the treatment of hemorrhagic fever caused by Filoviruses.  Financial terms of the agreement are not disclosed.  ...
Nov 08, 2016 04:15 pm ET
Dr. Kathryn C. Zoon Appointed to Emergent BioSolutions Board of Directors
GAITHERSBURG, Md., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Kathryn C. Zoon, Ph.D. to the company’s Board of Directors. Dr. Zoon is currently a Scientist Emeritus with the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). Dr. Zoon’s affiliation with NIH spans four decades, beginning with her early research alongside Nobel Laureate Christian B. Anfinsen. During her distinguished career, Dr. Zoon has held various leadership positions at NIH including Chief of the Cytokine...
Nov 07, 2016 04:15 pm ET
Emergent BioSolutions Reports Third Quarter and Nine Months 2016 Financial Results
GAITHERSBURG, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2016....
Nov 01, 2016 07:00 am ET
Emergent BioSolutions to Release Third Quarter 2016 Financial Results and Conduct a Conference Call on November 7, 2016
GAITHERSBURG, Md., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will release its financial results for the third quarter on Monday, November 7, 2016 and host a conference call at 5:00 pm (Eastern Time). In the press release and on the conference call, the Company will discuss its financial results for the quarter and year-to-date periods of 2016, provide an update on the status of guidance, highlight recent business developments, and review the remaining 2016 operational goals....
Oct 04, 2016 09:55 am ET
Lawsuit for Investors in Emergent Biosolutions Inc (NYSE:EBS) announced by Shareholders Foundation
SAN DIEGO, Oct. 04, 2016 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending in Maryland on behalf of certain purchasers of shares of Emergent Biosolutions Inc (NYSE:EBS) over alleged Securities Laws Violations by Emergent Biosolutions Inc. The lawsuit seeks to recover damages for certain NYSE:EBS investors....
Sep 30, 2016 09:28 am ET
Emergent BioSolutions Provides Update on Status of BioThrax Procurement Contract and Discussions With CDC
GAITHERSBURG, Md., Sept. 30, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today provided an update on the status of its 2011 BioThrax® (Anthrax Vaccine Adsorbed) procurement contract and the status of its discussions with the Centers for Disease Control and Prevention (CDC) for a follow-on procurement contract for BioThrax....
Sep 30, 2016 09:04 am ET
Emergent BioSolutions Awarded BARDA Contract for Advanced Development and Delivery of NuThrax, a Next Generation Anthrax Vaccine, Valued at Up to $1.6 Billion
GAITHERSBURG, Md., Sept. 30, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), which is a division of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, for the advanced development and delivery of NuThraxTM (anthrax vaccine adsorbed with CPG 7909 adjuvant), also known as AV7909, the company’s next generation anthrax vaccine candidate. The contract, valued at up to approximately $1.6 bi...
Sep 16, 2016 10:39 am ET
Sep 13, 2016 01:54 pm ET
Sep 12, 2016 05:22 pm ET
Brower Piven Alerts Shareholders of September 19, 2016 Deadline in Class Action Lawsuit and Encourages Those With Losses in Excess of $100,000 From Investment in Emergent BioSolutions, Inc. to Contact
STEVENSON, Md., Sept. 12, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland, Southern Division, on behalf of purchasers of Emergent BioSolutions, Inc. (NYSE:EBS) (“Emergent” or the “Company”) common stock during the period between January 11, 2016 and June 21, 2016, inclusive (the “Class Period”).  Emergent is headquartered in Gaithersburg, Maryland.  Brower Piven is the only firm headquartered in Maryland with a pr...
Sep 08, 2016 09:30 am ET
INVESTOR ALERT: Hagens Berman Reminds Emergent Biosolutions, Inc. (NYSE: EBS) Investors of September 19, 2016 Lead Plaintiff Deadline
SAN FRANCISCO, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Emergent Biosolutions, Inc. (NYSE:EBS) that the Lead Plaintiff Deadline is September 19, 2016 in the securities class action pending in the United States District Court for the District of Maryland....
Sep 07, 2016 02:22 pm ET
INVESTOR ALERT: Rosen Law Firm Reminds Emergent BioSolutions, Inc. Investors of Important September 19 Deadline in Class Action - EBS
NEW YORK, Sept. 7, 2016 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Emergent BioSolutions, Inc. common stock (NYSE: EBS) from January 11, 2016 through June 21, 2016, both dates inclusive (the "Class Period") of the important September 19, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Emergent BioSolutions investors under the federal securities laws....
Sep 02, 2016 10:07 pm ET
EMERGENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against E
NEW ORLEANS, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 19, 2016 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions, Inc. (NYSE:EBS), if they purchased the Company’s securities between January 11, 2016 and June 21, 2016, inclusive (the “Class Period”).  This action is pending in the United States District Court for the District of Maryland....
Sep 02, 2016 10:10 am ET
FINAL DEADLINE ALERT:  Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Emergent Biosolutions, Inc (EBS) & Lead Plaintiff Deadline - September 19, 2016
NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed in the United States District Court District of Maryland on behalf of those who purchased shares of Emergent Biosolutions, Inc. (“Emergent” or the “Company”) (NYSE:EBS) during the period between January 11, 2016 and June 21, 2016, inclusive (the “Class Period”). ...
Sep 01, 2016 03:10 pm ET
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Emergent BioSolutions Inc. Of Upcoming Deadline
WILMINGTON, Del., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.:...
Aug 31, 2016 03:51 pm ET
SHAREHOLDER ALERT: Rosen Law Firm Reminds Emergent BioSolutions, Inc. Investors of Important September 19 Deadline in Class Action - EBS
NEW YORK, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Emergent BioSolutions, Inc. common stock (NYSE:EBS) from January 11, 2016 through June 21, 2016, both dates inclusive (the “Class Period”) of the important September 19, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Emergent BioSolutions investors under the federal securities laws....
Aug 31, 2016 11:08 am ET
EBS INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Emergent Biosolutions Inc. and a Lead Plaintiff Deadline of September 19, 2016
NEW YORK, Aug. 31, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Maryland on behalf of investors who purchased Emergent Biosolutions Inc. (NYSE: EBS) securities between January 11, 2016 and June 21, 2016....
Aug 26, 2016 12:55 pm ET
Purcell Julie & Lefkowitz LLP Is Investigating Emergent BioSolutions Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, Aug. 26, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Emergent BioSolutions Inc. (NYSE: EBS). ...
Aug 17, 2016 11:07 am ET
EBS INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Emergent Biosolutions Inc. and a Lead Plaintiff Deadline of September 19, 2016
NEW YORK, Aug. 17, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Maryland on behalf of investors who purchased Emergent Biosolutions Inc. (NYSE:EBS) securities between January 11, 2016 and June 21, 2016....
Aug 15, 2016 04:20 pm ET
Emergent BioSolutions Receives FDA Approval for Large-Scale Manufacturing of BioThrax in Building 55
GAITHERSBURG, Md., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for the manufacture of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55, the company’s large-scale manufacturing facility located in its 12.5-acre campus in Lansing, Michigan....
Aug 12, 2016 04:50 pm ET
Emergent BioSolutions Announces Conversion Rate Adjustment to 2.875% Convertible Senior Notes Due 2021 Following Spin-Off of Aptevo Therapeutics
GAITHERSBURG, Md., Aug. 12, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that, as a result of the completion of the spin-off of Aptevo Therapeutics, the conversion rate for the company’s 2.875% Convertible Senior Notes due 2021 has been adjusted to 32.3860 shares of common stock per $1,000 principal amount, which is equivalent to a conversion price of approximately $30.88 per share of common stock, effective after market close on August 12, 2016....
Aug 12, 2016 12:25 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Emergent BioSolutions, Inc. - EBS
NEW YORK, Aug. 12, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Emergent BioSolutions, Inc. common stock (NYSE:EBS) from January 11, 2016 through June 21, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Emergent BioSolutions investors under the federal securities laws....
Aug 12, 2016 10:16 am ET
Aug 11, 2016 01:49 pm ET
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Emergent Biosolutions, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In
STEVENSON, Md., Aug. 11, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland, Southern Division, on behalf of purchasers of Emergent Biosolutions, Inc. (NYSE:EBS) (“Emergent” or the “Company”) common stock during the period between January 11, 2016 and June 21, 2016, inclusive (the “Class Period”). Emergent is headquartered in Gaithersburg, Maryland. Brower Piven is the only firm headquartered in Maryland with a pract...
Aug 10, 2016 07:00 am ET
CDC Exercises Contract Option Valued at $11.6 Million to Further Support Emergent BioSolutions’ Vaccinia Immune Globulin
GAITHERSBURG, Md., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the Centers for Disease Control and Prevention (CDC) has exercised a contract option valued at $11.6 million over 12 months under contract 200-2012-52242 for the supply of Vaccinia Immune Globulin (VIGIV) into the U.S. Strategic National Stockpile. VIGIV is a therapeutic licensed by the U.S. Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination. The contract option will require Emergent to conduct manufacturing runs and additional activ...
Aug 05, 2016 11:07 pm ET
EMERGENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against E
NEW ORLEANS, Aug. 5, 2016 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 19, 2016 to file lead plaintiff applications in a securities class action lawsuit against Emergent BioSolutions, Inc. (NYSE: EBS), if they purchased the Company's securities between January 11, 2016 and June 21, 2016, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Maryland. ...
Aug 05, 2016 09:30 am ET
INVESTOR ALERT: Hagens Berman Reminds Emergent Biosolutions, Inc. (NYSE: EBS) Investors of September 19, 2016 Lead Plaintiff Deadline
SAN FRANCISCO, Aug. 05, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Emergent Biosolutions, Inc. (NYSE:EBS) that the Lead Plaintiff Deadline is September 19, 2016 in the securities class action pending in the United States District Court for the District of Maryland....
Aug 04, 2016 04:15 pm ET
Emergent BioSolutions Reports Second Quarter and Six Months 2016 Financial Results
GAITHERSBURG, Md., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and six months ended June 30, 2016....
Aug 01, 2016 11:12 am ET
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Emergent Biosolutions Inc. of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 19, 2016 -- EBS
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Emergent Biosolutions Inc. ("Emergent Biosolutions" or the "Company") (NYSE: EBS) between January 11,...
Aug 01, 2016 07:00 am ET
Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics
GAITHERSBURG, Md., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed its previously announced spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through the distribution of all of the shares of Aptevo common stock to the holders of Emergent BioSolutions common stock. As a result of the spin-off, Aptevo is now an independent public company and listed on the Nasdaq Global Select Market under the ticker symbol “APVO.”...
Jul 29, 2016 10:07 pm ET
EMERGENT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against E
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 19, 2016 to file lead plaintiff applications in a securities class action lawsuit...
Jul 29, 2016 03:19 pm ET
Jul 25, 2016 10:42 am ET
EBS SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of Commencement of a Class Action Involving Emergent Biosolutions Inc. and a Lead Plaintiff Deadline of September 19, 2016
NEW YORK, July 25, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Maryland on behalf of investors who purchased Emergent Biosolutions Inc. (NYSE:EBS) securities between January 11, 2016 and June 21, 2016....
Jul 23, 2016 11:27 am ET
Long Term Emergent (EBS) Investors: Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigation of Emergent BioSolutions, Inc.; Encourages Long Term Investors to Contact the Firm
SAN DIEGO, July 23, 2016 /PRNewswire-USNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal and state securities laws by Emergent BioSolutions, Inc. (NYSE: EBS) and certain of its officers and board members. Emergent BioSolutions is a specialty biopharmaceutical company that develops, manufactures and sells specialized products to healthcare providers and governments....
Jul 22, 2016 11:10 pm ET
IMPORTANT NOTICE TO SHAREHOLDERS: Brower Piven, A Maryland-Based Securities Litigation Law Firm, Notifies Shareholders of Securities Class Action Lawsuit And Encourages Investors Who Have Losses In E
STEVENSON, Md., July 22, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland, Southern Division, on behalf of purchasers of Emergent Biosolutions, Inc. (NYSE:EBS) (“Emergent” or the “Company”) common stock during the period between January 11, 2016 and June 21, 2016, inclusive (the “Class Period”).  Emergent is headquartered in Gaithersburg, Maryland.  Brower Piven is the only firm headquartered in Maryland with a pra...
Jul 22, 2016 09:30 am ET
INVESTOR ALERT: Hagens Berman Alerts Emergent Biosolutions, Inc. (NYSE: EBS) Investors to Securities Class Action and September 19, 2016 Lead Plaintiff Deadline
SAN FRANCISCO, July 22, 2016 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors of Emergent Biosolutions, Inc. (NYSE:EBS) that a securities class action is pending in the United States District Court for the District of Maryland and the Lead Plaintiff Deadline is September 19, 2016....
Jul 21, 2016 04:15 pm ET
Emergent BioSolutions to Release Second Quarter 2016 Financial Results and Conduct a Conference Call on August 4, 2016
GAITHERSBURG, Md., July 21, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 4, 2016 at 5:00 pm (Eastern Time) to discuss the financial results for the second quarter of 2016, provide an update on the status of guidance, highlight recent business developments, and review the remaining 2016 operational goals....
Jul 21, 2016 03:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent Biosolutions, Inc. - EBS
NEW YORK, July 21, 2016 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Emergent Biosolutions, Inc. ("Emergent" or the "Company") (NYSE: EBS).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Jul 20, 2016 08:30 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Emergent BioSolutions, Inc. (EBS)
NEW YORK, July 20, 2016 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Emergent BioSolutions, Inc. (“Emergent” or the “Company”) (NYSE:EBS) in the United States District Court for the District of Maryland on behalf of purchasers of common stock of Emergent between January 11, 2016 and June 21, 2016, inclusive (the “Class Period”), seeking to pursue remedies under the Securities Exchange Act of 1934 (the “Exchange Act”)....
Jul 20, 2016 04:30 pm ET
Safirstein Metcalf LLP Announces That a Class Action Lawsuit Has Been Filed Against Emergent Biosolutions Inc. - EBS
NEW YORK, July 20, 2016 (GLOBE NEWSWIRE) -- Safirstein Metcalf LLP announces that a complaint has been filed on behalf of purchasers of Emergent Biosolutions Inc. (“Emergent”) (NYSE:EBS) common stock during the period between January 11, 2016 and June 21, 2016 (the “Class Period”).  This action was filed in the District of Maryland....
Jul 20, 2016 04:11 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Emergent Biosolutions, Inc (EBS) & Lead Plaintiff Deadline: September 19, 2016
NEW YORK, July 20, 2016 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court District of Maryland on behalf of those who purchased shares of Emergent Biosolutions, Inc. ("Emergent" or the "Company") (NYSE: EBS) during the period between January 11, 2016 and June 21, 2016, inclusive (the "Class Period")....
Jul 20, 2016 11:42 am ET
Jul 20, 2016 07:00 am ET
Emergent BioSolutions Announces Commencement of When Issued Trading of Aptevo Common Stock
GAITHERSBURG, Md., July 20, 2016 (GLOBE NEWSWIRE) -- In connection with the spin-off of Aptevo Therapeutics Inc. (Nasdaq:APVO) through a dividend distribution by Emergent BioSolutions Inc. (NYSE:EBS) of one share of Aptevo common stock for every two shares of Emergent common stock outstanding as of the close of business on July 22, 2016, Emergent announced that Aptevo common stock will commence trading today, July 20, 2016, on a “when issued” basis under the symbol “APVOV” on the Nasdaq Global Select Market. ...
Jul 19, 2016 11:00 pm ET
Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against Emergent Biosolutions Inc.
NEW YORK, July 19, 2016 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP ("Robbins Geller") (http://www.rgrdlaw.com/cases/emergent/) today announced that a class action has been commenced on behalf of purchasers of Emergent Biosolutions Inc. ("Emergent") (NYSE:EBS) common stock during the period between January 11, 2016 and June 21, 2016 (the "Class Period").  This action was filed in the District of Maryland and is captioned Sponn v. Emergent Biosolutions Inc., et al., No. 8:16-cv-02625-RWT....
Jul 15, 2016 01:16 pm ET
Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement
Aptevo Therapeutics common stock approved for listing on the NASDAQ Global Select Market GAITHERSBURG, Md., July 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Registration Statement on Form 10 filed by Aptevo Therapeutics Inc. has been declared effective by the U.S. Securities and Exchange Commission. The Registration Statement on Form 10, available at www.emergentbiosolutions.com/spinoff, includes material information regarding Aptevo’s business and spin-off, which is expected to be completed on August 1, 2016....
Jul 15, 2016 07:00 am ET
Emergent BioSolutions to Implement Stock Repurchase Program for Up to $50 Million of Its Common Stock
GAITHERSBURG, Md., July 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors has authorized the company’s management to implement a stock repurchase program for up to $50 million of the company's common stock from time to time on the open market or in privately negotiated transactions....
Jul 11, 2016 07:00 am ET
Emergent BioSolutions’ Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio
GAITHERSBURG, Md., July 11, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that, on July 10, 2016, its Board of Directors approved the spin-off of Aptevo Therapeutics Inc. and declared a dividend distribution of one share of Aptevo common stock for every two shares of Emergent common stock outstanding as of the close of business on July 22, 2016, the record date for the distribution. Emergent expects to complete the distribution of Aptevo common stock to Emergent stockholders on August 1, 2016....
Jul 01, 2016 11:38 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Emergent Biosolutions, Inc (EBS)
NEW YORK, July 1, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Emergent Biosolutions, Inc. ("Emergent" or the "Company") (NYSE: EBS). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484....
Jun 27, 2016 09:00 am ET
Emergent BioSolutions Receives BARDA Task Order Valued at Up to $21.9 Million to Develop and Manufacture a Zika Vaccine
GAITHERSBURG, Md., June 27, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Center for Innovation in Advanced Development and Manufacturing (CIADM) has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $21.9 million to develop and manufacture three cGMP lots of a Zika vaccine for use in a Phase 1 clinical trial. Using a base vaccine candidate provided by BARDA, the company will conduct technology transfer of process materials and information, process and analytical method development, execut...
Jun 22, 2016 08:32 am ET
U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of Anthrax Vaccines
GAITHERSBURG, Md., June 22, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that on June 21, 2016, the U.S. Department of Health and Human Services (HHS) issued two solicitation notices with respect to the development and procurement of anthrax vaccines for the Strategic National Stockpile (SNS). The company believes that taken together, these two solicitations represent the government’s intent to establish and maintain a stockpile of anthrax vaccines capable of protecting 25 million people through the continued procurement of 29.4 million doses of BioThrax® ...
Jun 21, 2016 07:00 am ET
FDA Completes Pre-Approval Inspection of Emergent BioSolutions’ Large-Scale Manufacturing Facility for BioThrax
GAITHERSBURG, Md., June 21, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has completed its Pre-Approval Inspection (PAI) of Building 55, the company’s facility for large-scale manufacturing of BioThrax® (Anthrax Vaccine Adsorbed). At the conclusion of the inspection, the company received a No Action Indicated decision and no Form 483 observations. Successful completion of the PAI is one of the requirements for Building 55 licensure in connection with the company's supplemental Biologics License Application (...
Jun 17, 2016 07:00 am ET
FDA Accepts Emergent BioSolutions’ Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55
GAITHERSBURG, Md., June 17, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent’s supplemental Biologics License Application (sBLA) seeking approval of the manufacture of BioThrax® (Anthrax Vaccine Adsorbed) in Building 55, the company’s large-scale manufacturing facility. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016....
Jun 15, 2016 07:00 am ET
Emergent BioSolutions Receives FDA Orphan Drug Status for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease
GAITHERSBURG, Md., June 15, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug status for BioThrax® (Anthrax Vaccine Adsorbed) for post-exposure prophylaxis (PEP) of anthrax disease resulting from suspected or confirmed exposure to Bacillus anthracis. The Orphan Drug status provides market exclusivity through November 2022, representing seven years from the date on which FDA approved the PEP indication for BioThrax. The FDA Orphan Drug Designation program provides a special status to drugs ...
May 05, 2016 04:15 pm ET
Emergent BioSolutions Reports First Quarter 2016 Financial Results
Q1 2016 financial performance in line with guidanceCDC notifies the Company of its intent to award a follow-on BioThrax procurement contract on October 1, 2016In transitioning to the follow-on contract, the Company is temporarily postponing its 2016 financial guidance until CDC confirms level of Q2 and Q3 BioThrax procurement GAITHERSBURG, Md., May 05, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter ended March 31, 2016....
May 04, 2016 04:15 pm ET
Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available
GAITHERSBURG, May 04, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2016 beginning at 9:00 AM Eastern at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814....